hile coronavirus in the US is undoubtedly a setback for the...

hile coronavirus in the US is undoubtedly a setback for the company, we expect these to be temporary in nature given RECELL’s unique product proposition in terms of clinically proven benefits (significantly reduced donor skin requirements). Peer-reviewed studies have also supported RECELL’s favourable cost-benefit profile for hospitals given reduced patient length of stay.

For example, our survey of US surgeons indicates that over 85 per cent of users have noticed a somewhat or significant beneficial impact on time to healing for patients, with additional positive outcomes on patient comfort (more than 75 per cent), scarring (more than75 per cent) and satisfaction (more than 70 per cent). The survey helps to confirm a number of the claims by the company with regards to length of stay, fewer procedures and cost savings, while the key claim on reduction of donor skin is the basis for FDA approval.